Results 181 to 190 of about 24,764 (229)
Some of the next articles are maybe not open access.
Sulfinpyrazone: An Antiarrhythmic Drug?
Pacing and Clinical Electrophysiology, 1982The patients were studied by intracardiac electrocardiography and programmed stimulation before and after an intravenous bolus injec tion of either 500 mg sulfinpyrazone or a placebo. We found no consistent clinical or statistical effects of sulfinpyrazone on sinus rate, sinus node recovery time, sinoatrial conduction time, conduction intervals during ...
J C, Roos, A J, Dunning
openaire +2 more sources
The American Journal of Surgery, 1983
Great advances have been made in our understanding of cardiac arrhythmias and the effect of drugs on these arrhythmias. Several new types of antiarrhythmic drugs have been introduced. For example, encainide, flecainide, or lorcainide are new type I drugs that exert their major effects on depressing cardiac conduction.
M M, Scheinman, D S, Hess
openaire +2 more sources
Great advances have been made in our understanding of cardiac arrhythmias and the effect of drugs on these arrhythmias. Several new types of antiarrhythmic drugs have been introduced. For example, encainide, flecainide, or lorcainide are new type I drugs that exert their major effects on depressing cardiac conduction.
M M, Scheinman, D S, Hess
openaire +2 more sources
Future of antiarrhythmic drugs
Current Opinion in Cardiology, 2006This article briefly summarizes the principal mechanisms of action of contemporary antiarrhythmic agents, delineates their limitations in the treatment of cardiac arrhythmias, and discusses why there is a need for new cardiac antiarrhythmic drugs.In recent years, the limited efficacy and proarrhythmic potential of classic antiarrhythmic drugs have ...
Dawood, Darbar, Dan M, Roden
openaire +2 more sources
The American Journal of Cardiology, 1989
Clinical failure of antiarrhythmic drugs often occurs in practice. Therefore, there is a need for new, effective and long-acting drugs with a wide therapeutic range and a low level of toxicity. Most new class I compounds block the fast sodium ion inward current of myocardial cells.
P, Jaillon, M, Drici
openaire +2 more sources
Clinical failure of antiarrhythmic drugs often occurs in practice. Therefore, there is a need for new, effective and long-acting drugs with a wide therapeutic range and a low level of toxicity. Most new class I compounds block the fast sodium ion inward current of myocardial cells.
P, Jaillon, M, Drici
openaire +2 more sources
Current Treatment Options in Cardiovascular Medicine, 2006
The use of antiarrhythmic drugs can be challenging to physicians. They are effective in treating various types of arrhythmias, yet their potential to cause adverse events, in particularly proarrhythmia, can be intimidating. When the decision to use antiarrhythmic therapy has been made, physicians are confronted with several issues: choosing the right ...
Brian R, Triola, Peter R, Kowey
openaire +2 more sources
The use of antiarrhythmic drugs can be challenging to physicians. They are effective in treating various types of arrhythmias, yet their potential to cause adverse events, in particularly proarrhythmia, can be intimidating. When the decision to use antiarrhythmic therapy has been made, physicians are confronted with several issues: choosing the right ...
Brian R, Triola, Peter R, Kowey
openaire +2 more sources
Medical Clinics of North America, 1988
The effective management of cardiac arrhythmias remains a major challenge in cardiovascular therapeutics. The management of arrhythmias encompasses a wide spectrum of supraventricular and ventricular tachyarrhythmias occurring in patients with various cardiac diagnoses and different degrees of myocardial dysfunction.
E L, Michelson, L S, Dreifus
openaire +2 more sources
The effective management of cardiac arrhythmias remains a major challenge in cardiovascular therapeutics. The management of arrhythmias encompasses a wide spectrum of supraventricular and ventricular tachyarrhythmias occurring in patients with various cardiac diagnoses and different degrees of myocardial dysfunction.
E L, Michelson, L S, Dreifus
openaire +2 more sources
The Journal of Clinical Pharmacology, 1989
Discussion sur l'efficacite d'un traitement antiarrythmique apres un infarctus du myocarde, sur la diminution de la mortalite chez les malades. Difficulte pratique d'effectuer un essai avec la flecainide et l'encainide, due a la mauvaise information des ...
openaire +2 more sources
Discussion sur l'efficacite d'un traitement antiarrythmique apres un infarctus du myocarde, sur la diminution de la mortalite chez les malades. Difficulte pratique d'effectuer un essai avec la flecainide et l'encainide, due a la mauvaise information des ...
openaire +2 more sources